A RANDOMIZED PHASE-II STUDY OF ACIVICIN AND 4'DEOXYDOXORUBICIN IN PATIENTS WITH HEPATOCELLULAR-CARCINOMA IN AN EASTERN COOPERATIVE ONCOLOGY GROUP-STUDY

被引：41

作者：

FALKSON, G

CNAAN, A

SIMSON, IW

DAYAL, Y

FALKSON, H

SMITH, TJ

HALLER, DG

机构：

[1] HARVARD UNIV,SCH PUBL HLTH,DANA FARBER CANC INST,BOSTON,MA 02115

[2] TUFTS UNIV,BOSTON,MA

[3] HOSP UNIV PENN,PHILADELPHIA,PA 19104

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1990年 / 13卷 / 06期

关键词：

D O I：

10.1097/00000421-199012000-00012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We analyzed 56 of 75 previously untreated patients with hepatocellular carcinoma who entered on a prospectively randomized trial of acivicin versus 4'deoxydoxorubicin (esorubicin). At least one episode of severe toxicity was documented in 23% of the patients on acivicin and 45% of those on 4'deoxydoxorubicin. Two patients responded to 4'deoxydoxorubicin. One response was partial, lasting 58 weeks, and one was complete, lasting more than 4 years. The 90% confidence interval for response is 1-20%. In view of a 45% rate of severe or worse toxicity with 4'deoxydoxorubicin, this drug cannot be recommended as treatment. There were no responses on acivicin.

引用

页码：510 / 515

页数：6

共 12 条

[1]

ACRAMORE F, 1976, J MED CHEM, V19, P1424

[2]

Agresti A., 1984, ANAL ORDINAL CATEGOR

[3]

CASSAZA AM, 1980, ANTHRACYLINE CURRENT, P403

[4]

Cox DR, 1984, ANAL SURVIVAL DATA, pviii

[5]

FALKSON G, 1988, CANCER RES, V48, P7314

[6]

HAWKA LJ, 1973, ANTIMICROB AGENTS CH, V3, P425

[7]

HAWKA LJ, 1973, CAN CHEMOTHER REP, V57, P141

[8]

HOUCHENS D, 1978, P AM ASSOC CANC RES, V19, P40

[9]

JAYARAM HN, 1975, CANCER CHEMOTH REP 1, V59, P481

[10] A NETWORK ALGORITHM FOR PERFORMING FISHER EXACT TEST IN R X C CONTINGENCY-TABLES [J].

MEHTA, CR ;

PATEL, NR .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1983, 78 (382) :427-434

← 1 2 →